For patients in the hospital, eculizumab is Formulary, Restricted to use for PNH & aHUS indications, with specialist approval.

• Epysqli® is the preferred product at Legacy, when eculizumab is used in the hospital

• Eculizumab requires patient and provider REMS enrollment prior to dispensing 

• Patients should be up to date with meningococcal vaccinations against A, C, W, Y and B prior to treatment initiation.   

• • Patients should receive their meningococcal vaccinations at least 2 weeks prior to treatment initiation.  

• • If meningococcal vaccinations not up to date, prophylactic antibiotics should be initiated and administer meningococcal vaccines as soon as possible. 

• Epysqli® (eculizumab-aagh) Risk Evaluation and Mitigation Strategy (REMS) webpage
  • Website outlines REMS requirements and documentation needed for dispensing   

• Epysqli® (eculizumab-aagh) REMS Healthcare Provider Safety Brochure 

• Combined Ultomiris® (ravulizumab) and Soliris® (eculizumab) Risk Evaluation and Mitigation Strategy (REMS) webpage             
  • Website outlines REMS requirements and documentation needed for dispensing   

• Combined Ultomiris® and Soliris® REMS Healthcare Provider Safety Brochure  

See REMS Requirements Chart for Details